Brasada Capital Management LP Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Brasada Capital Management LP invested approximately $4.51 million in Thermo Fisher Scientific Inc. by acquiring 9,053 shares in the first quarter.
• Thermo Fisher reported earnings of $5.36 per share for the last quarter, surpassing analysts’ estimates, with revenue reaching $10.86 billion.
• The company has declared a quarterly dividend of $0.43 per share, set to be paid on October 15th, representing a 0.3% yield.

Brasada Capital Management LP bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,053 shares of the medical research company's stock, valued at approximately $4,505,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after purchasing an additional 257,462 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Thermo Fisher Scientific by 9.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,419,617 shares of the medical research company's stock worth $1,204,002,000 after purchasing an additional 215,232 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $3.31 during mid-day trading on Monday, hitting $493.05. The stock had a trading volume of 1,228,194 shares, compared to its average volume of 1,834,312. The firm has a market capitalization of $186.18 billion, a P/E ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $454.36 and its 200 day moving average is $453.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock valued at $13,603,438 in the last three months. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on TMO. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Raymond James Financial restated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.